CoChat

BET bromodomain proteins are required for glioblastoma cell proliferation

Open access
Pastori, Chiara, Daniel, Mark, Penas, Clara, Volmar, Claude-Henry, Johnstone, Andrea L, Brothers, Shaun P, Graham, Regina M, Allen, Bryce, Sarkaria, Jann N, Komotar, Ricardo J, Wahlestedt, Claes, Ayad, Nagi G · 2014 · Epigenetics
Cited by 144

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Epigenetic proteins have recently emerged as novel anticancer targets. Among these, bromodomain and extra terminal domain (BET) proteins recognize lysine-acetylated histones, thereby regulating gene expression. Newly described small molecules that inhibit BET proteins BRD2, BRD3, and BRD4 reduce proliferation of NUT (nuclear protein in testis)-midline carcinoma, multiple myeloma, and leukemia cells in vitro and in vivo. These findings prompted us to determine whether BET proteins may be therapeutic targets in the most common primary adult brain tumor, glioblastoma (GBM). We performed NanoString analysis of GBM tumor samples and controls to identify novel therapeutic targets. Several cell proliferation assays of GBM cell lines and stem cells were used to analyze the efficacy of the drug I-BET151 relative to temozolomide (TMZ) or cell cycle inhibitors. Lastly, we performed xenograft experiments to determine the efficacy of I-BET151 in vivo. We demonstrate that BRD2 and BRD4 RNA are significantly overexpressed in GBM, suggesting that BET protein inhibition may be an effective means of reducing GBM cell proliferation. Disruption of BRD4 expression in glioblastoma cells reduced cell cycle progression. Similarly, treatment with the BET protein inhibitor I-BET151 reduced GBM cell proliferation in vitro and in vivo. I-BET151 treatment enriched cells at the G1/S cell cycle transition. Importantly, I-BET151 is as potent at inhibiting GBM cell proliferation as TMZ, the current chemotherapy treatment administered to GBM patients. Since I-BET151 inhibits GBM cell proliferation by arresting cell cycle progression, we propose that BET protein inhibition may be a viable therapeutic option for GBM patients suffering from TMZ resistant tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/epi.27906

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 144

Metadata

Authors
Pastori, C., Daniel, M., Penas, C., Volmar, C.-H., Johnstone, A. L., Brothers, S. P., Graham, R. M., Allen, B., Sarkaria, J. N., Komotar, R. J., Wahlestedt, C., & Ayad, N. G.
Venue
Epigenetics
Published
2014-02-19
Volume
9
Issue
4
Pages
611-620
ISSN
  • 1559-2294 (ISSN-L)
  • 1559-2308
OpenAlex
W2038607889
Cited by
144
References
9
FWCI
6.33
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BET bromodomain proteins are required for glioblastoma cell proliferation. https://app.cochat.ai/papers/10.4161/epi.27906
The paper
Pastori, C., Daniel, M., Penas, C., Volmar, C.-H., Johnstone, A. L., Brothers, S. P., Graham, R. M., Allen, B., Sarkaria, J. N., Komotar, R. J., Wahlestedt, C., & Ayad, N. G. (2014). BET bromodomain proteins are required for glioblastoma cell proliferation. Epigenetics. https://doi.org/10.4161/epi.27906

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.